摘要:
The invention relates to prodrugs of pharmacologically active, five-membered heterocyclic amidines from which in vivo compounds are obtained, these compounds being competitive inhibitors of trypsin-type serin proteases, especially thrombin and kininogenases such as kallikrein. The invention also relates to the production of these prodrugs and to their use as medicaments, to pharmaceutical compositions that contain the prodrugs of the active compounds as components, and to the use of the compounds as thrombin inhibitors, anticoagulants and anti-inflammatory agents.
摘要:
The invention relates to compounds of the formula A-B-D-E-F, in which A, B, D, E and F have the meanings given in the description, and to their production. These new compounds are suitable for producing medicines.
摘要:
The invention relates to ancrod specific monoclonal antibodies, antibody fragments, mixtures or derivatives thereof and the use thereof in pharmaceutical preparations or in diagnostics. The invention also relates to cells which express said antibodies, antibody fragments and mixtures or derivatives thereof.
摘要:
Compounds having the formula (I) are disclosed, in which the substituents have the meanings given in the description, as well as their salts with physiologically acceptable acids and their stereoisomers, and intermediate products for producing the same. These compounds are useful for treating diseases.
摘要:
The invention relates to the use of modulators of cytokine mediated signalling pathways in combination with integrin αvβ3 receptor antagonists for the treatment or prevention of diseases, particularly to the use of pharmaceutical composition, comprising a modulator of cytokine mediated signalling pathways and an integrin αvβ3 receptor antagonist, for the treatment or prevention of inflammatory or autoimmune disorders, particularly for the treatment or prevention of rheumatoid arthritis and to the pharmaceutical composition itself.
摘要:
Disclosed are compounds having formula (I) wherein the radicals R, R?1, R2, R3, R4, R5 and R6¿, as well as l, m, and n have the meaning indicated in the description, and the production of said compounds. The new compounds can be used to combat illness. Also described are compounds having formula (II) wherein the radicals R, R?1, R2, R3, R4, R5 and R6¿, as well as l, m, and n have the meaning indicated in claim 1, and compounds having formula (III) wherein l and R have the meaning indicated in claim 1 and Y is an N protective group, or N-terminal protected or unprotected amino acid or represents H.
摘要:
Disclosed are compounds having formula (I) wherein the radicals R, R?1, R2, R3, R4, R5 and R6¿, as well as l, m, and n have the meaning indicated in the description, and the production of said compounds. The new compounds can be used to combat illness. Also described are compounds having formula (II) wherein the radicals R, R?1, R2, R3, R4, R5 and R6¿, as well as l, m, and n have the meaning indicated in claim 1, and compounds having formula (III) wherein l and R have the meaning indicated in claim 1 and Y is an N protective group, or N-terminal protected or unprotected amino acid or represents H.
摘要:
The invention concerns thrombin inhibitors of formula (I), wherein R1, A, B, and D have the meanings given in the description, and intermediate products for the preparation thereof. The compounds of formula (I) are suitable for combating diseases.